[萨希妥珠单抗戈维替康对一名三阴性乳腺癌患者的长期疗效和安全性,该患者接受过多种治疗且体重指数较高。]

Q3 Medicine Recenti progressi in medicina Pub Date : 2024-11-01 DOI:10.1701/4365.43617
Maria Morritti
{"title":"[萨希妥珠单抗戈维替康对一名三阴性乳腺癌患者的长期疗效和安全性,该患者接受过多种治疗且体重指数较高。]","authors":"Maria Morritti","doi":"10.1701/4365.43617","DOIUrl":null,"url":null,"abstract":"<p><p>The metastatic triple negative breast cancer (mTNBC) represents a particularly aggressive form of breast cancer that frequently affects young women under the age of 50. Obesity at the time of breast cancer diagnosis is associated with a worse prognosis. Compared to the recent past, increasing life expectancy and quality of life for patients with mTNBC is now a possible challenge, thanks to a new drug, sacituzumab govitecan (SG), an anti-Trop-2 antibody drug conjugate approved as monotherapy for the treatment of these patients. The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 11","pages":"110e-115e"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index.]\",\"authors\":\"Maria Morritti\",\"doi\":\"10.1701/4365.43617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The metastatic triple negative breast cancer (mTNBC) represents a particularly aggressive form of breast cancer that frequently affects young women under the age of 50. Obesity at the time of breast cancer diagnosis is associated with a worse prognosis. Compared to the recent past, increasing life expectancy and quality of life for patients with mTNBC is now a possible challenge, thanks to a new drug, sacituzumab govitecan (SG), an anti-Trop-2 antibody drug conjugate approved as monotherapy for the treatment of these patients. The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.</p>\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"115 11\",\"pages\":\"110e-115e\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4365.43617\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4365.43617","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

转移性三阴性乳腺癌(mTNBC)是一种侵袭性特别强的乳腺癌,经常侵袭 50 岁以下的年轻女性。乳腺癌确诊时的肥胖与预后较差有关。与过去相比,现在有了一种新药--sacituzumab govitecan(SG),它是一种抗肿瘤坏死因子-2(Trop-2)的抗体药物共轭物,已被批准作为治疗这类患者的单一疗法。本临床病例记录了一位已接受过多种治疗的年轻肥胖 mTNBC 女性患者接受 SG 长期治疗的有效性和安全性。经过 20 个月的治疗后,患者的反应仍然良好,生活质量和社会交往状况良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index.]

The metastatic triple negative breast cancer (mTNBC) represents a particularly aggressive form of breast cancer that frequently affects young women under the age of 50. Obesity at the time of breast cancer diagnosis is associated with a worse prognosis. Compared to the recent past, increasing life expectancy and quality of life for patients with mTNBC is now a possible challenge, thanks to a new drug, sacituzumab govitecan (SG), an anti-Trop-2 antibody drug conjugate approved as monotherapy for the treatment of these patients. The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
期刊最新文献
(Con)fine della salute: restituzione del lavoro di un ambulatorio popolare dai margini della città. [GLP-1 agonists reduce the risk of major cardiovascular events in older patients with type 2 diabetes, and SGLT2 inhibitors prevent hospitalizations for acute heart failure.] [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.] [Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.] [Patients with heart failure experience fewer hospitalizations and reduced mortality when treated with mineralocorticoid receptor antagonists.]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1